This protocol describes how to image protein-protein interactions using a FRET-based proximity assay.
Protein-protein interactions are a hallmark of all essential cellular processes. However, many of these interactions are transient, or energetically weak, preventing their identification and analysis through traditional biochemical methods such as co-immunoprecipitation. In this regard, the genetically encodable fluorescent proteins (GFP, RFP, etc.) and their associated overlapping fluorescence spectrum have revolutionized our ability to monitor weak interactions in vivo using Förster resonance energy transfer (FRET)1-3. Here, we detail our use of a FRET-based proximity assay for monitoring receptor-receptor interactions on the endothelial cell surface.
The protocol consists of three major steps. The first, step cloning of your gene of interest into a mammalian expression vector amino-terminally to the monomeric versions of CFP and/or YFP will only be discussed briefly. The second and third steps; transfection of vector DNA into EA.hy926 endothelial cells, and confocal imaging with FRET, are outlined in more depth below.
1. Construction of CFP and YFP Chimeric Receptors
Receptors of interest should be cloned amino-terminally to monomeric enhanced versions of CFP and YFP. Determination of FRET is empirical and is critically dependent upon the length of linker between the transmembrane spanning region and start of the fluorophore1. Therefore, several different lengths of linker must be explored for each new receptor pair under investigation.
2. Transfection of EA.hy 926 Cells
3. Confocal Imaging and FRET Analysis
Live cell imaging is performed on a Leica TCS-SP2 AOBS confocal laser scanning microscope equipped with blue diode (405 nm), Argon (458, 476, 488, 514 nm). green HeNe (543 nm), orange HeNe (594 nm), and red HeNe (633 nm) lasers, an HCX PI Apo 63x/1.3 n.a. glycerin-immersion objective lens, a motorized XY stage (Märzhäuser), and an environmentally controlled (temperature, humidity, and CO2) stage incubator (PeCon). Experimental controls are critical to eliminate fluorophore cross-talk between the emission channels as well as to evaluate expression issues and non-specific fluorophore multimerization. As such, single fluorophore transfections are utilized for setting up every image session. Negative FRET controls (using known noninteracting receptors) will need to be performed, in order to determine the background FRET that occurs due to over expression.
4. Representative Results
Transfection efficiencies are usually between 30 to 40%. Despite previous findings by others, we have not seen that transfection and expression of one vector favors that of the other. Indeed, we frequently observe exclusive expression of one fluorophore chimera or the other. Typical FRET efficiencies vary among receptor systems. For the Tie receptor system, typical values are 20-28% for epithelial cells and 19-23% in endothelial cells. For negative controls, typical efficiencies are below 2-3%. The extent of variability will decrease considerably with experience.
Figure 1. Representative images of transfected EA.hy 926 cells. A) DIC image of EA.hy 926 cell monolayer. B) Fluorescence image of cells displayed in (A). C) Overlay of (A) and (B) demonstrating ~20-30% transfection efficiency.
Figure 2. Representative acceptor photo-bleaching analysis of FRET occurring between CFP and YFP in an EA.hy926 cell. The CFP emission channel (top panels) and YFP emission channel (bottom two panels) were monitored separately prior to and post acceptor photobleaching. Photobleaching experiments were restricted to, and FRET values calculated from, the region within the green box. FRET efficiency is displayed as an absolute range from high (red-1.0) to low (purple-0.0) on a magnified overlay of a CFP/YFP merged image for orientation purposes only.
There are several steps that are critical to success. The most prominent among them is the relative levels of expression between the two chimeric receptors. To circumvent this issue, one may make stable cell lines expressing both proteins of interest, or identify optimal ratios of vector DNA to permit equivalent expression. Similarly, due to non-uniform transfection across a dish, protein levels will seldom be equivalent among cells. Therefore, attention must be paid to distinguish ‘high’ expressors from ‘low’. Those that display ‘average’ levels of protein typically yield reliable and reproducible FRET efficiencies. One method our lab has pursued to relieve this issue is the use of adeno and lenti-viruses to ‘even’ gene expression. Furthermore, an alternative method to acceptor photo-bleaching for determining FRET efficiencies is sensitized emission. Although, despite the potential of sensitized emission to monitor single cells in real-time, we have found acceptor photo-bleaching to be more sensitive and more reliable.
Finally, using FRET to monitor protein interactions can be challenging, and requires careful selection of linker lengths for membrane bound receptors. Furthermore, addition of C/YFP often greatly influences protein expression levels and results in aggregation in the endoplasmic reticulum and golgi apparatus. However, for transient, or unstable, interactions, FRET is the ideal methodology to utilize.
The authors have nothing to disclose.
We wish to acknowledge Dr Scott Henderson for help with confocal microscopy. This research was supported by grants from the National Institutes of Health 1RO1CA127501 to W.A.B as well as pilot project funding from the Massey Cancer Center and School of Medicine (VCU) to W.A.B. Microscopy was performed at the VCU-Dept. of Neurobiology & Anatomy Microscopy Facility, supported, in part, with funding from NIHNINDS Center core grant 5P30NS047463.
Material Name | Tipo | Company | Catalogue Number | Comment |
---|---|---|---|---|
DMEM | Invitrogen | 11960-069 | ||
Penicillin- Streptomycin | Invitrogen | 15070-063 | ||
Fetal Bovine Serum | Hyclone | N/A | ||
Opti-MEM | Invitrogen | 11058-021 | ||
FUGENE 6 | Roche | 11814443001 | ||
Coverslip Dishes | MatTek Corp. | P35G014C | ||
pcDNA3.1(+) | Invitrogen | V790‐20 | ||
Mach 1 Competent Cells | Invitrogen | C862003 |